News brief­ing: Mer­ck preps FDA pitch af­ter adding more da­ta on V114; Bris­tol My­ers, Ex­elix­is get quick re­view for can­cer com­bo

Mer­ck has new da­ta out from two Phase III tri­als on its pneu­mo­coc­cal con­ju­gate vac­cine can­di­date cov­er­ing 15 dif­fer­ent serotypes.

The pro­gram, dubbed V114, was test­ed in the first study in healthy adults aged 50 or old­er, with pa­tients re­ceiv­ing ei­ther the ex­per­i­men­tal vac­cine or the ap­proved Pre­vnar 13, fol­lowed by Mer­ck’s Pneu­movax 23 vac­cine one year lat­er. Af­ter that pe­ri­od, im­mune re­spons­es were com­pa­ra­ble in both vac­ci­na­tion groups for the 15 serotypes in V114.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER